Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 trial of BOLD 100 in combination with a proteasome inhibitor (e.g., Velcade (bortezomib) or Kyprolis (carfilzomib)) in the treatment of multiple myeloma

Next Previous
Trial Profile

A Phase 2 trial of BOLD 100 in combination with a proteasome inhibitor (e.g., Velcade (bortezomib) or Kyprolis (carfilzomib)) in the treatment of multiple myeloma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BOLD 100 (Primary) ; Bortezomib (Primary) ; Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Bold Therapeutics

Most Recent Events

  • 17 May 2022 New trial record
  • 10 May 2022 According to a Bold Therapeutics media release, the company is actively seeking global development partners in Q4 2022 to support this two additional parallel Phase 2 studies.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top